Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Neoplasms 2Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Breast Neoplasms 1

Interventions

Rituximab 67Cyclophosphamide 52fludarabine phosphate 44Whole-Body Irradiation 36Mycophenolic Acid 33Peripheral Blood Stem Cell Transplantation 29Tacrolimus 27Busulfan 24Cyclosporine 21Antilymphocyte Serum 21Melphalan 18Filgrastim 16Etoposide 15Methotrexate 14Radiotherapy 12Lenalidomide 12Cord Blood Stem Cell Transplantation 12fludarabine 10Sirolimus 10Granulocyte Colony-Stimulating Factor 10Dexamethasone 9Bendamustine Hydrochloride 9Prednisone 8Bortezomib 8thymoglobulin 7idelalisib 7Flow Cytometry 7Calcium Dobesilate 7ibritumomab tiuxetan 6Methylprednisolone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, B-Cell, Marginal Zone × cirmtuzumab × Clear all
NCT03088878 2025-02-12

A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Oncternal Therapeutics, Inc

Phase 1/2 Completed
95 enrolled 25 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡